Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
Status:
Active, not recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if the combination of Paclitaxel once per week with
Pembrolizumab once every 3 weeks will help participants with this disease. Researchers want
to find out the effectiveness of the drug combination to improve the delay of cancer
progression or death and compare it to historical data for weekly paclitaxel alone, and
assess safety.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute